Abstract: The present invention discloses a method for improving the blood compatibility of a material surface by using a controllable grafting technique. The method involves placing a monomer NVP, an RAFT reagent and a solvent acetonitrile in a container, adding an initiator AIBN, mixing the same uniformly, removing oxygen with liquid nitrogen, making the same react in an oil bath; after polymerization, adding liquid nitrogen to quench and stop the reaction, thus obtaining PVP-COOH; mixing the PVP-COOH with DCC and NHS; adding dry dichloromethane to the mixture in a nitrogen atmosphere, adding mercaptoethylamine, and making the same react in darkness at room temperature; obtaining a crude sample; dissolving the crude sample in water, and performing dialysis with deoxygenated water in darkness, and then obtaining HS-PVP by freeze-drying. An Au—S bond chemisorption method is used to controllably graft an anti-protein high-molecular polymer onto an Au surface.

Abstract: A fault current limiter, including: two inductors, a direct current circuit breaker, a shunt resistor, a first fixed resistor, and metal oxide arresters. The two inductors include wound superconducting wires. The inductors have identical number of windings and identical structure. Magnetic fluxes of the inductors are forward coupled, and the inductors are connected in parallel to form a superconducting inductor structure. The direct current circuit breaker and the superconducting inductor structure are connected in series to form a series branch. The shunt resistor is connected in parallel to the series branch. The first fixed resistor is connected in parallel to the direct current circuit breaker. The metal oxide arresters are two in number, and are connected to two ends of the inductors in parallel.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

Abstract: Provided are methods for quantifying and/or detecting sub-visible particulates in cell cultures. Specifically, the methods comprise a step of breaking down, e.g., lysing, cells in a cell culture. The methods can further comprising filtering the cell culture through a filter. Further provided are methods of quantifying sub-visible particulates that do not pass through the filter using a microscope.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: The present invention discloses a method for preparing an anti-bacterial surface on a medical material surface, including the steps of: (1) conducting chemical graft of amino silane after performing oxygen plasma pretreatment to the medical material surface and then reacting the medical material with the amino silane surface with an acyl compound; (2) placing the medical material with an initiator-modified surface into an anti-adhesion monomer aqueous solution for a graft polymerization reaction; (3) placing the medical material with an anti-adhesion polymer brush-modified surface into an azide compound-containing dimethylformamide solution; and (4) placing the medical material with an azide surface into an anti-bacterial agent click solution for a click reaction, obtaining an anti-adhesion polymer layer—and anti-bacterial agent layer-comodified anti-bacterial surface.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

Abstract: A fault current limiter, including: an inductor, a direct current circuit breaker, a shunt resistor, and a first fixed resistor. The inductor includes wound superconducting wires. The direct current circuit breaker and the inductor are connected in series to form a series branch. The shunt resistor is connected in parallel to the series branch. The first fixed resistor is connected in parallel to the direct current circuit breaker.

Abstract: The present application discloses a gas logging system, including a degasser configured to degas a sample to separate a gas to be tested; and a detector connected to the degasser and configured to receive the gas to be tested separated by the degasser and perform detection, where the degasser comprises a degassing cover, the degassing cover includes a spherical crown disk surface and a plurality of semipermeable membrane degassing units on the spherical crown disk surface, wherein the plurality of semipermeable membrane degassing units are arranged on the spherical crown disk surface according to the Fibonacci Spiral Rule. The gas logging system provided by the present application may improve the distribution uniformity of a drilling fluid on the degassing cover while increasing arrangement number, and reduce the impact on semipermeable membrane degassing units.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: A memory protection device is used for protecting a memory. The memory protection device includes a filtering unit and an encoding unit. The filtering unit searches an input data and outputs an encoding selection signal based on a bit component pattern of the input data. The encoding unit selects one or more encoding implementations among a plurality of encoding implementations based on the encoding selection signal from the filtering unit, to encode the input data.

Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Abstract: Broadly neutralizing antibodies against HIV-1 which specifically bind to gp120 of HIV-1, a method of preparing such antibodies and the use thereof are provided.

Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.